Oramed Pharmaceuticals Inc. (ORMP)
Chart Events
Performance Outlook
| Previous Close | 2.7800 |
| Open | 2.8700 |
| Bid | 3.3200 x 800 |
| Ask | 3.4200 x 1300 |
| Day's Range | 2.8500 - 3.3300 |
| 52 Week Range | 2.4000 - 6.0500 |
| Volume | 682,137 |
| Avg. Volume | 157,423 |
| Market Cap | 75.992M |
| Beta (5Y Monthly) | 1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5690 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.67 |
- PR Newswire
Oramed Initiates Phase 3 Trial of Oral Insulin
Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D). The patients were screened at U.S. sites participating in Oramed's ORA-D-013-1 trial, one of two Phase 3 trials being conducted in accordance with U.S. Food and Drug Administration approved protocols.
- PR Newswire
Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020
Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Nobel Laureate Prof. Avram Hershko and Oramed Chief Scientific Officer Dr. Miriam Kidron will join Premas Biotech's Co-Founder and Managing Director Dr. Prabuddha Kundu and Co-Founder and Chief Operating Officer Dr. Nupur Mehrotra in Part 2 of a webinar titled "Oral Delivery of Therapeutic Proteins - Oramed Story" on Wednesday, November 18, 2020 at 10:00 a.m. ET. Prof. Hershko is a member of the Oramed Scientific Advisory Board.
- PR Newswire
Oramed to Present at H.C. Wainwright 6th Annual Israel Conference
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwright 6th Annual Israel Conference.
